News : 2017 : July

A Scholar Rock antibody (in orange) is shown binding to the myostatin precursor (in green and yellow) to prevent release of myostatin's muscle growth-prevention activity.

Drug Candidate Shows Therapeutic Potential in Preclinical Model of Spinal Cord Injury

The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine and Scholar Rock, a biotechnology company, have announced findings from a research collaboration that has demonstrated beneficial effects of a proprietary antibody in a preclinical model of spinal cord injury.

Read more »